Peptides and nanoparticles for therapeutic and diagnostic applications
Provided herein are peptides and nanoparticles conjugates thereof useful for the treatment of diseases and disorders mediated by GIPC/synectin, such as cancer.
1. A bioconjugate comprising a metal nanoparticle bound to at least one peptide, wherein said peptide
comprises the amino acid sequence of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10 or SEQ ID NO:11, or a pharmaceutically acceptable salt thereof.
2. A peptide
comprising the amino acid sequence of SEQ ID NO:9, SEQ ID NO:10 or SEQ ID NO:11, or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition comprising the bioconjugate of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
4. A pharmaceutical composition comprising the peptide of claim 2 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
5. A method for treating pancreatic cancer, wherein said cancer overexpresses GAIP interacting protein (GIPC), comprising administering to a patient in need thereof a therapeutically effective amount of a bioconjugate of claim 1 , or a pharmaceutically acceptable salt thereof.
6. A method for treating pancreatic cancer, wherein said cancer overexpresses GAIP interacting protein (GIPC), comprising administering to a patient in need thereof a therapeutically effective amount of a peptide of claim 2 , or a pharmaceutically acceptable salt thereof.
7. A bioconjugate comprising a metal nanoparticle bound to at least one peptide, wherein said peptide is My-SESPSASQ (SEQ ID NO:23), or a pharmaceutically acceptable salt thereof.
8. A peptide comprising the amino acid sequence of My-SESPSASQ (SEQ ID NO:23), or a pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition comprising the bioconjugate of claim 7 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
10. A pharmaceutical composition comprising the peptide of claim 8 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
11. A method for treating breast or pancreatic cancer, wherein said cancer overexpresses GAIP interacting protein (GIPC), comprising administering to a patient in need thereof a therapeutically effective amount of a bioconjugate of claim 7 , or a pharmaceutically acceptable salt thereof.
12. A method for treating breast or pancreatic cancer, wherein said cancer overexpresses GAIP interacting protein (GIPC), comprising administering to a patient in need thereof a therapeutically effective amount of a peptide of claim 8 , or a pharmaceutically acceptable salt thereof.